CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 64 enrolled
Drug / intervention
Fluticasone furoate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00584987
NCT00584987Phase 4Completed
CompareCT.gov

A Combination of Intranasal Steroid/Oxymetazoline Leads to Faster Relief of Nasal Congestion Without Inducing Rhinitis Medicamentosa

University of Chicago·interventional·Posted Jan 2, 2008·Updated Dec 17, 2013

In Brief

A Phase 4 clinical trial evaluating Fluticasone furoate, Placebo Fluticasone furoate, and 2 other interventions for Allergic Rhinitis. Completed, enrolled 64 participants across 1 site.

Detailed Summary

We hypothesize that once daily use of oxymetazoline will not cause significant rhinitis medicamentosa and that the combination of fluticasone furoate plus oxymetazoline leads to faster relief of nasal congestion secondary to perennial allergic rhinitis than the use of fluticasone furoate alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2, 2008
Enrollment StartJun 1, 2007
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.5 years ago

Interventions

Fluticasone furoatedrug

2 puffs of each nasal spray in each nostril in the pm

Placebo Fluticasone furoatedrug

2 puffs of each nasal spray in each nostril in the pm

Oxymetazolinedrug

2 puffs of each nasal spray in each nostril in the pm

Placebo Oxymetazolinedrug

2 puffs of each nasal spray in each nostril in the pm